Latest Compumedics (ASX:CMP) News

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Compumedics has landed a $4.2 million order for its advanced MEG system from Shandong Normal University, pushing total contracted MEG sales to around $30 million and extending revenue visibility into FY27.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

A takeover offer lit up small caps, while one high-growth software name slid hard despite strong sector news. Resources dominated the winners list, but investors still punished dilution and discounted fundraisings.

Compumedics has delivered record first-half sales orders and a 32% jump in shipped revenue, setting the stage for a robust second half driven by new product launches and operational efficiencies.

Compumedics has landed a $4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, pushing total MEG sales in China to $25 million and reinforcing its leadership in the Asian neuro-imaging market.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Compumedics has secured FDA clearance for its single-use Somfit®D device, effectively doubling its addressable U.S. home sleep testing market to an estimated US$240 million annually. This milestone positions the company to capture significant market share with a dual-platform EEG-based solution.

Compumedics has reported record-breaking sales orders and revenues for FY25, driven by strong US market growth and SaaS adoption, setting the stage for an ambitious FY26 expansion.

Compumedics Limited reported a 2% revenue increase and a 22% jump in sales orders for FY25, driven by strong demand in sleep diagnostics and SaaS platforms, while navigating a net loss impacted by higher financing costs.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.